Earnings Call Summary | Bioceres Crop Solutions(BIOX.US) Q3 2024 Earnings Conference
Earnings Call Summary | Bioceres Crop Solutions(BIOX.US) Q3 2024 Earnings Conference
The following is a summary of the Bioceres Crop Solutions Corp. (BIOX) Q3 2024 Earnings Call Transcript:
以下是Bioceres Crop Solutions Corp.（BIOX）2024年第三季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Bioceres reported Q3 revenues of $84 million, marking a 10% decrease compared to the same quarter the previous year.
The company's net income for this period decreased to $9.8 million, and their adjusted EBITDA fell to $21.1 million.
The drop in figures has been attributed entirely to the disproportionate weight of the Syngenta distribution agreement in the Q3 earnings of the previous year.
Despite some delayed sales of bio-nutrition solutions in Argentina and Brazil, the company anticipates these to be realized in Q4.
Bioceres expects an improvement in their final fiscal quarter, with around $4 million EBITDA not realized in the third quarter but expected in the current one. For HB4 wheat, $15 million EBITDA is targeted.
Bioceres公佈的第三季度收入爲8400萬美元，與去年同期相比下降了10％。
該公司同期的淨收入降至980萬美元，調整後的息稅折舊攤銷前利潤降至2,110萬美元。
數字下降完全歸因於先正達分銷協議在去年第三季度收益中的比例不成比例。
儘管在阿根廷和巴西推遲了生物營養解決方案的銷售，但該公司預計這些解決方案將在第四季度實現。
Bioceres預計其最後一個財季將有所改善，第三季度未實現約400萬美元的息稅折舊攤銷前利潤，但預計本季度將實現。HB4小麥的目標是1500萬美元的息稅折舊攤銷前利潤。
Business Progress:
業務進展：
Bioceres received their first regulatory approval for bio-control solutions in Brazil, entering high-value bio-insecticidal markets.
Their first two HB4 soy varieties, limitedly used by key farmers in Brazil, have received positive feedback with some reporting double-digit yield improvement.
Significant developments in the Seed and Integrated Products segment, mostly connected to HB4 wheat sales, are expected to drive profitability growth in Q4.
The company is expanding into the U.S. market, albeit HB4 product development there lags behind Latin America. It awaits the USDA approval for domestic production of HB4 wheat but expects significant growth upon approval of new product formulations.
In Brazil, approvals for products Venerate and Majestene are expected to expand the company's portfolio and will not cannibalize current sales due to already established relationships.
Bioceres首次獲得巴西生物控制解決方案的監管批准，進入了高價值的生物殺蟲劑市場。
他們的前兩個HB4大豆品種僅限於巴西的主要農民使用，獲得了積極的反饋，其中一些人報告了兩位數的產量提高。
種子和綜合產品板塊的重大發展主要與HB4小麥銷售有關，預計將推動第四季度的盈利能力增長。
該公司正在向美國市場擴張，儘管那裏的HB4產品開發落後於拉丁美洲。它正在等待美國農業部批准HB4小麥的國內產量，但預計新產品配方獲得批准後將大幅增長。
在巴西，Venerate和Majestene產品的批准預計將擴大公司的產品組合，並且不會因爲已經建立的關係而蠶食當前的銷售。
More details: Bioceres Crop Solutions IR
更多詳情： Bioceres 作物解決方案 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。